View Clinical Trial (Medical Research Study)

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL) - NCT00774345-54601(Clinical Trial 326879)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  La Crosse
State:  
WI
Zip Code: 54601
Conditions: B-cell Chronic Lymphocytic Leukemia
Purpose: The purpose of this study is to determine if lenalidomide (Revlimid®) is safe and effective as a maintenance therapy at improving further the quality of the response you achieved with your last therapy and at prolonging the duration of your response. This study will compare the effects (good and bad) of lenalidomide with the dummy drug.
Study summary:
Criteria: Inclusion Criteria: 1. Must sign an informed consent form. 2. Age ≥ 18 years 3. Must be able to adhere to the study visit schedule and other protocol requirements. 4. Must have a documented diagnosis of B-cell CLL. 5. Must have been treated with a purine analog- or bendamustine- containing regimen in the first and/or second line induction therapy. Alemtuzumab-containing regimens in place of purine analog- or bendamustine- containing regimens will also be allowed for those patients with 17p deletion. 6. Must have achieved a minimum of partial response following completion of second-line induction therapy. 7. Must have an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2. 8. Must agree to follow pregnancy precautions as required by the protocol. 9. Must agree to receive counseling related to teratogenic and other risks of lenalidomide. 10. Must agree not to donate blood, eggs or sperm as defined by the protocol Exclusion Criteria: 1. Any medical condition, that would prevent the subject from signing the informed consent form. 2. Active infections requiring systemic antibiotics. 3. Systemic infection that has not resolved > 2 months prior to initiating lenalidomide 4. Autologous or allogeneic bone marrow transplant as second line therapy. 5. Pregnant or lactating females. 6. Participation in any clinical study or having taken any investigational therapy within 28 days. 7. Known presence of alcohol and/or drug abuse. 8. Central nervous system (CNS) involvement. 9. Prior history of malignancies, other than CLL, unless the subject has been free of the disease for ≥3 years. Exceptions include the following: - Basal cell carcinoma of the skin - Squamous cell carcinoma of the skin - Carcinoma in situ of the cervix - Carcinoma in situ of the breast - Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b) 10. History of renal failure requiring dialysis. 11. Know Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV) and/or active Hepatitis C Virus (HCV) infection. 12. Prior therapy with lenalidomide. 13. Presence of specific hematology and/or chemistry abnormalities 14. Severe rash due to prior thalidomide treatment 15. Uncontrolled hyperthyroidism or hypothyroidism 16. Venous thromboembolism within one year 17. ≥ Grade-2 neuropathy 18. Uncontrolled autoimmune hemolytic anemia or thrombocytopenia
Study is available at: Gundersen Lutheran Clinic, Ltd.
La Crosse, WI 54601
United States

Primary Contact:
Jorge Mouro, MS
Email: jmouro@celgene.com
Phone: 011-908-673-2252
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.